Biopharma financings during the first quarter of 2022 reached $17.9bn, led by cell therapy player Altos Labs, which raised $3bn in its initial funding round, the only known venture financing to exceed the billion-dollar mark.
Venture capital financings overall made up the greatest proportion of the financing dollars, with early- and late-stage VC rounds together...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?